Description
Biotinylated Human B7-1 / CD80 Protein, Fc, Avitag™ (MALS verified) | B71-H82F2-200ug| Gentaur Distribution US, UK & Europe
B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
Source: Biotinylated Human B7-1, Fc, Avitag (B71-H82F2) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # NP_005182.1).
Format: Powder.
Tag: C-Fc & C-Avi.
Expression System: HEK293.
Expression Region: Val 35 - Asn 242.
Conjugate: Biotin-labeled.
Molecular Weight: 52.3 kDa.
Characteristics: This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 52.3 kDa. The protein migrates as 65-95 kDa under reducing (R) condition, and 130-160 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Purity: 95%.
Buffer: Tris with Glycine, Arginine and NaCl, pH7.5.
Storage Conditions: -20℃.
Shipping Conditions: RT